Aligos Therapeutics Inc
NASDAQ:ALGS 4:00:00 PM EDT
| Market Cap (Intraday) | 44.84M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $13.86 |
| 50-Day MA | $13.01 |
| 200-Day MA | $16.91 |
Aligos Therapeutics Inc Stock, NASDAQ:ALGS
1 Corporate Drive, 2nd floor, South San Francisco, California 94080
United States of America
Phone: +1.800.466.6059
Number of Employees: 66
Description
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.